IHS Chemical Week

Regions :: Western Europe :: Switzerland

Oxford BioTherapeutics Licenses Lonza’s GS Gene Expression System

12:08 AM MDT | September 2, 2011 | Deepti Ramesh

Lonza says it has signed a non-exclusive license agreement with biotechnology company Oxford BioTherapeutics (OBT; Abingdon, U.K.) that will provide OBT with access to Lonza’s GS Gene Expression System. The agreement covers the research, development and commercial use of the GS system by OBT. Financial details of the deal were not disclosed.  The GS Gene Expression System is used for the production of therapeutic recombinant proteins and monoclonal antibodies. Licensing of the GS Gene Expression System expands OBT’s access to technologies for its...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa